Trial Profile
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Mavorixafor (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors X4 Pharmaceuticals
- 15 Nov 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 13 Jul 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.